Skip to main content

Multiple Myeloma

Selinexor Combined with Pomalidomide and Dexamethasone for Treatment of Patients with RRMM

In Patients with RRMM, Cobimetinib as a Single Agent and Combined with Venetoclax with or without Atezolizumab

In Patients with RRMM, Treatment with Venetoclax plus Daratumumab and Dexamethasone ± Bortezomib

BELLINI Study: Venetoclax versus Placebo in Combination with Bortezomib/Dexamethasone in Patients with RRMM

Melflufen plus Dexamethasone and Daratumumab or Bortezomib

HORIZON: Use of Melflufen plus Dexamethasone in Patients with RRMM Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody

Patients with Newly Diagnosed Transplant-Eligible MM and Minimal Residual Disease after Treatment with Ixazomib, Lenalidomide, and Dexamethasone

TOURMALINE-MM4 Study: Patients with NDMM Not Treated with Stem-Cell Transplantation and Maintenance Therapy with Ixazomib

FORTE Trial: Analysis of Survival in Patients with Newly Diagnosed Transplant-Eligible MM

In Newly Diagnosed, Transplant-Eligible Patients with MM, Consolidation Treatment with VRD Followed by Lenalidomide Maintenance versus Maintenance Alone

6
7
8
9
10
11

Page 9 of 11
Results 81 - 90 of 104